Vera Therapeutics: the PDUFA is today

Vera Therapeutics: the PDUFA is today

Vera Therapeutics ($VERA) has a catalyst-driven setup centered on the July 7, 2026 PDUFA for atacicept in IgA nephropathy, with the Phase 3 eGFR readout expected close behind in Q3 2026. The bull case rests on ORIGIN 3, where UPCR fell 46% versus 7% on placebo at week 36. The bear case is simpler: investors still do not have the Phase 3 kidney-function endpoint they actually care about.

Gobble's Take: Classic "prove it now, explain it later" stock — and the market's patience for that combination runs notoriously thin. Source: BIOTECH MARKET RESEARCH

Tesla beat expectations. The market sold it anyway.

Trader attention shifted in June, and Tesla stayed center stage — delivery numbers blew past Wall Street's expectations, then the stock sold off. That is the kind of reaction that keeps people arguing with the chart instead of reading it.

Gobble's Take: When great numbers get a cold shoulder, the chart is talking. Most people just don't want to listen. Source: Everyone's Watching These Stocks

Digestion, not breakdown

The broader tape is sideways digestion inside a bigger uptrend, with indices holding above the 50-day since the start of June. QQQ has two major high-volume closes clustered around $705–$707, with $705 as the line. Tesla had a quick pump and dump around $391.95. The summary: nothing has broken, and the danger zones remain untested.

Gobble's Take: The market is catching its breath — not throwing in the towel. Source: Stock's Newsletter

More information is not a strategy

The problem isn't a shortage of market data — it's the opposite. Investors absorb inflation prints, jobs reports, Fed commentary, yield curve chatter, commodity moves, analyst upgrades, geopolitical headlines, options flows, meme stock spikes, and a river of opinions dressed up as insight. The framework that cuts through all of it is subtraction, not addition: four signals, nothing more, and stop mistaking information overload for sophistication.

Gobble's Take: A crowded framework fails exactly when you need it most. Clean it up before the market does it for you. Source: The Only 4 Market Signals I Track (Everything Else Is Noise)

In Case You Missed It

Yesterday's top stories:

• Market Breadth is still holding up
• The watchlist crowd is getting a reminder to focus
• QQQ is still the line in the sand